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Currently, Hodgkin's lymphoma is one of the most curable types of cancer. Patients are often
young and so the long-term morbidities of treatment have become of increasing concern. Among
these, infertility is one of the most challenging consequences for patients in reproductive age.
Premature ovarian failure in premenopausal women is a serious long-term sequel of the toxicity
of chemotherapy. The main consequence of this syndrome is infertility, but women also present
other symptoms related to estrogen deprivation. Different rates of impaired gonadal function are
reported, depending on the patient's age, stage of disease, dose and intensity of chemotherapy and
the use of radiation therapy. The most established strategy in female infertility is cryopreservation
of embryos after in vitro fertilization. Additionally, the use of oral contraceptives or gonadotropin-
releasing hormone analogs (GnRH-a) during treatment is under study. This review will provide
a general overview of the main studies conducted to evaluate the infertility rate among female
Hodgkin's lymphoma survivors and risk factors associated to treatment, different end-point
definitions for evaluating fertility and also a brief description of the available strategies for fertility
preservation.
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Introduction
Due to the large body of randomized trials conducted by cooperative groups in
North America and Europe, the outcome of Hodgkin's lymphoma (HL) has greatly improved
over recent decades and HL is today among the most curable malignancies. However,
new strategies for further improving HL outcomes in patients should take into account
two major concerns: first, a reduction in long-term treatment-related toxicity and second,
a decrease in the failure rate for advanced stages.(1)
Among the complications, infertility is one of the most challenging consequences
for patients in reproductive age. In female survivors, one of major concerns is the risk of
premature ovarian failure (POF).(2) POF is defined as the premature termination of ovarian
function of peripheral origin and is a serious long-term sequel of toxicity. The main
consequence of this syndrome is infertility, but women also present symptoms related to
estrogen deprivation, such as osteoporosis. Different rates of secondary amenorrhea
are reported, depending on the patient's age, stage of disease, dose and intensity of
chemotherapy and use of radiation therapy. The most established strategy in female
infertility is the cryopreservation of embryos after in vitro fertilization. Also, the use of
oral contraceptives or gonadotropin-releasing hormone analogs (GnRH-a) during
treatment aimed at preventing secondary ovarian failure is under study.(3-5)
This review will provide a general overview of the main studies conducted to
evaluate the frequency of infertility among female HL survivors and risk factors associated
to treatment, different end-point definitions for evaluating fertility and also, a brief
description of the methods of fertilization preservation.
General issues and definitions
The ovaries contain a pool of primordial follicles that decreases during life. At
birth, there are about two million follicles, whereas 200 000 remain at puberty and 25 000
at the age of 37 years-old. At the time of menopause there is a pool of fewer than 1000
follicles, when the follicle-stimulating hormone (FSH) levels are insufficient due to
declining estrogen levels.(6)
The number of remaining follicles in the ovaries is called the ovarian reserve and
represents the woman's current reproductive capacity. The anti-Mullerian hormone (AMH)
is produced by early follicles. It has an inhibitory effect on primordial follicle recruitment
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as well as on the responsiveness of growing follicles to
FSH. Its level declines with age and becomes undetectable
after menopause.
In premenopausal women, ovarian function is
controlled by FSH and luteinizing hormone (LH) produced
in the pituitary. FSH activates the granulosa cells of growing
ovarian follicles, which proliferate and produce estradiol.
This reduces the levels of FSH by feedback inhibition, thus
keeping them at low levels. LH at the middle of the cycle
induces ovulation following the formation of the luteal body
that produces progesterone. The growing follicles also
produce inhibin, which prevents an overgrowth of follicles
by down regulating FSH.(7)
The main consequence of POF is infertility, but
women may also present hot flushes, atrophic vaginitis
and osteoporosis. Cancer treatment may induce acute
ovarian failure (AOF) shortly after the conclusion of
treatment.(8,9)  A proportion of these women resume normal
menses within months. Among women who maintain ovarian
function after the end of treatment, some may present a
premature menopause before the age of 40 years old. In
addition to the impact on the quality of life, premature
menopause may increase the risk of cardiovascular disease
and osteoporosis.(9)
Infertility risk factors
Age
Age and the status of the ovarian reserve before
treatment are risk factors for POF in HL. Some studies
reported an increase in risk in over 30-year-old women,
but this is probably an arbitrary cut-off. Age-related
gonadal injury may also be influenced by a natural decline
in fertility with increased age. Younger women tolerate
higher cumulative doses of chemotherapy before
developing amenorrhea and have a greater chance of
resuming menses after treatment. On the other hand, older
women, who have an already depleted number of follicles
at the onset of treatment, are more susceptible to gonadal
toxicity.(3,8,10)
Treatment
While it is well-established that combination
chemotherapy causes depletion of the ovarian follicle
reserve, the gonadotoxicity of each agent is not easy to
establish. Alkylating agents are most often associated with
dose-dependent and irreversible gonadal toxicity. The risk
of POF is about 50% in young women receiving
cyclophosphamide at a mean cumulative dose of 9.3 g.
Moreover, there is an 11% increase in the risk of POF with
each additional 1.4 g/m2 of cumulative procarbazine.(3,8,10) A
summary of the risks of premature menopause of each drug
is shown in Table 1.
Currently, ABVD (doxorubicin, bleomycin, vinblastine,
dacarbazine) and escalated  BEACOPP (bleomycin,
etoposide, doxorubicin, cyclophosphamide, vincristine,
procarbazine, prednisone) are the most frequently used
regimens for treating HL.(1) In general, ABVD is not
associated with a greater risk of premature menopause.
Hodgson et al. reported the results of a case-control study
of thirty-six female HL survivors who had attempted
pregnancy and found no evidence of significant impairment
in fertility compared to controls.(11) The German Hodgkin
Study Group (GHSG) analyzed the menstrual status after HL
treatment of 405 patients.(10) They found a proportion of
51.4% of the women who had received eight cycles of
escalated BEACOPP had permanent amenorrhea.  The
escalated regimen produced a higher rate of amenorrhea than
standard BEACOPP.
In a large cohort of 518 female HL survivors, after a
median follow-up of 9.4 years, 97 women  reached menopause
before the age of 40 years.(8) Chemotherapy was associated
with a 12.3-fold increase in premature menopause, when
compared to radiotherapy alone.  Also, abdominal or pelvic
radiation increases the risk of POF.
The literature concerning the risks of infertility after
hematopoietic cell transplantation (HCT) is scarce. Some
studies have pointed out that the risk with allogeneic stem-
cell transplantation is the highest, especially after total
body irradiation (TBI). However, a report from the Late
Effects Working Committee of the Center for International
Blood and Marrow Transplant Research (CIBMTR)
revealed the occurrence of 83 pregnancies in female HCT
recipients. The series included recipients of autologous
HCT, myeloablative allogeneic HCT and non-myeloablative
allogeneic HCT.(12)
A summary of the main studies about risk factors of
impaired gonadal function in female HL patients is presented
in Table 2.
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Evaluation of fertility
Infertility is defined as the failure to conceive after one
year of regular intercourses without taking contraceptive
measures. Infertility secondary to cancer treatment may be
transient, permanent or delayed.(5)
The diagnosis of POF is based on clinical and
laboratory evidence. Ovarian reserve tests (ORT) include
ultrasound and serum biomarkers.(4,8,17)
Clinical evidence is based on the presence or absence
of menstrual cycles. After treatment, the recovery of normal
menstrual cycles does not warrant normal fertility, but
amenorrhea is the strongest predictor of infertility. Also, the
presence of transient amenorrhea after treatment is a risk
factor for subsequent infertility.(4,17)
Laboratory evidence includes determining the serum
levels of FSH, AMH and inhibin B. Usually, levels of FSH
are elevated in cases of impaired fertility, but normal levels
do not exclude impaired ovarian function. The AMH is
undetectable after menopause. Also, the level of inhibin,
which is secreted by the follicles, decreases with age.
Moreover, transvaginal ultrasound has been evaluated
in the diagnosis of POF. The antral follicle count (AFC) and
also the ovarian volume are useful parameters associated
with ovarian reserve and fertility.(18)
It is also known that patients with Hodgkin's lymphoma
may face infertility at the time of diagnosis, that is, before
treatment. Data come mostly from studies performed in men,
but it is possible that similar mechanisms operate in women.
Some studies evaluating semen quality before treatment
showed that most patients had azoospermia or dyspermia.
The underlying mechanism of infertility in HL patients is
still unknown. Possible factors are damage to the germinal
epithelium and disorders of the hypothalamic-hypophysial
axis as well as the impact of cytokines on spermatogenesis.(19)
Fertility preservation strategies
Assisted reproduction
The most established strategy for female infertility is
assisted reproduction (embryo and oocyte cryopreservation).
However, this approach has some limitations. Only pubertal
patients and patients with a long-term partner can benefit
from this procedure. Also, patients presenting an urgent
medical complication cannot wait for the delay imposed by
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the procedure, since the process usually requires a delay of
one month before starting chemotherapy. Alternatives under
study are fertilization of oocytes by intracytoplasmic sperm
injection and oocyte vitrification.(4,20)
Cryopreservation of ovarian tissue
This represents an investigational method offered to
pre-pubertal and pubertal females. The general principle is
to remove the ovary or obtain an ovarian cortex biopsy
and freeze the primordial follicles using established
protocols. Nevertheless, only 12 full-term pregnancies
using this method have been reported so far, and among
them only 4 in patients with HL. So, the results are still
uncertain.(4,21-23)
Pharmacological methods –
Gonadotropin-releasing hormone analogues
(GnRH) and oral contraceptives
There are many suggested mechanisms of protection
against gonadotoxicity by GnRH-a.(24) The first is the
creation of a hormonal milieu similar to the pre-pubertal state.
It has been hypothesized that chemotherapy induces an
accelerated rate of follicular destruction with subsequent
decreases in the production of estradiol and inhibin resulting
in increases in FSH production. This increase in FSH causes
enhanced recruitment of follicles and subsequent
destruction. The administration of GnRH or oral
contraceptives may prevent the increased levels of FSH by
inducing pituitary desensitization, thus protecting the
follicles. Another possible mechanism is decreased utero-
ovarian perfusion. It has been speculated that this decrease
in perfusion could reduce the exposure of ovaries to
chemotherapeutic agents.  Finally, a potential direct effect
on GnRH receptors has been proposed.
Several studies have been published to establish the
role of GnRH-a and oral contraceptives in preserving fertility
in female cancer patients. However, the literature is still
controversial.(24,25) In a retrospective study, GNRH-a allowed
the recovery of menses in 92% of patients and all 13 patients
that attempted pregnancy conceived.(3) In another
prospective study, 97% of patients taking GnRH-a resumed
ovulation and regular menses compared with 63% control
subjects.(26) On the other hand, a randomized prospective trial
aimed to compare oral contraceptives and GNRH-a in female
HL patients treated with escalated BEACOPP was recently
closed because neither arm protected ovarian function as
measured by AMH levels.(27) Furthermore, the authors that
are against the recommendation of the use of GnRH for young
female patients outside clinical trials argue that: (i) most of
the data came from retrospective studies with limited
numbers of patients, (ii) there is a lack of prospective,
randomized clinical trials, (iii) there is a lack of biological
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plausibility for protection by GnRH and also, (iv) there are
concerns about the safety of the procedure.(25) On the other
hand, some other authors consider that the published clinical
studies provide some evidence that GnRH-a reduces
gonadotoxicity and GnRH-a can even reduce some
chemotherapy-induced complications, such as severe
menometrorrhagia. In 2011, the results of a randomized trial,
PROMISE-GIM6, showed that the use of triptorelin during
chemotherapy in premenopausal patients with early-stage
breast cancer reduced the occurrence of early chemotherapy-
induced menopause. A summary of the main studies is
presented in Table 3.
Impairment of reproductive function can be a
significant late effect of cancer treatment, mainly for young
female patients. Understanding the major risk factors and
the role of alternative strategies such as the use of GnRH-a
or oral contraceptives during treatment will help prevent
gonadal damage. The benefits and risks of each treatment
regimen must be discussed individually, mainly with female
patients older than 30 years old and those receiving
alkylating-containing regimens. Also, if available, patients
should be offered assisted reproductive consultations.
Finally, a careful assessment of the ovarian function before
treatment should be performed in all circumstances and
the collection of such information should be encouraged
when planning prospective clinical trials as well as
lymphoma registries.
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